Journal of Psoriasis and Psoriatic Arthritis · 2022 · 23 citations · 106 references
MedicineImmunologyPharmacotherapyImmunotherapyInflammationRheumatologyCytokine BiologyCytokine-based TherapyInflammatory Disease PharmacotherapyInflammatory Skin DiseasesInflammatory Skin DisordersPsoriatic ArthritisBiologic Anti-inflammatory TherapiesInterleukin 23 InhibitionInterleukin-17 InhibitorsInterleukin-23 InhibitorsMalignancy Risk AssessmentPsoriasis TherapyPsoriatic DiseaseUstekinumab Therapy
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic therapies are approved. Over the past decade, studies have documented the higher efficacy of IL-17 and IL-23 inhibitors for the treatment of psoriasis compared to the TNF-alpha inhibitors and ustekinumab, an IL-12/23 inhibitor. Despite this, there remains an important role for the use of TNF-alpha inhibitors and ustekinumab in the treatment of psoriasis. Here, we review how considerations of infection and malignancy risk, patient demographics, treatment resistance, and co-morbidities may make certain TNF-alpha inhibitors or ustekinumab an excellent choice for therapy in particular patient subgroups.
106
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn, Brian G. Feagan, Paul Rutgeerts et al. · New England Journal of Medicine · 2013 · 2.7K citations · Full text
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Dermatology, Immunology +14
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Brian G. Feagan, William J. Sandborn, Christopher Gasink et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text